A5078932218- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Ubiquitin and proteasome pathways
- Advanced biosensing and bioanalysis techniques
- Cancer therapeutics and mechanisms
- Glycosylation and Glycoproteins Research
- Protein Tyrosine Phosphatases
- CRISPR and Genetic Engineering
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
Zhujiang Hospital
2023-2025
Southern Medical University
2023-2025
There is currently a lack of efficacious treatments for patients with chemo-resistant small-cell lung cancer (SCLC), leading to poor prognoses. We examined SCLC cell line using genome-wide CRISPR/Cas9 screening and identified serine/threonine kinase division cycle 7 (CDC7) as potential synergistic target. Silencing CDC7 in cells decreased the IC50 improved efficacy chemotherapy. Based on highest single agent model, inhibitor XL413 had effect both cisplatin etoposide cells, but no such...
Our study elucidates the role of FOXP1 in chemoresistance small cell lung cancer(SCLC). enhances by regulating SP8 expression through its super-enhancer (SP8-SE), with mediating resistance via homologous recombination repair (HRR) pathway. We also discovered that forms punctate nuclear structures indicative liquid-liquid phase separation, crucial for transcriptional regulation. Targeting FOXP1-SP8-HR axis BRD4 and PARP inhibitors showed synergistic effects reducing tumor growth vitro...
Small cell lung cancer (SCLC) is characterized by rapid development of chemoresistance and poor outcomes. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used in breast other types. However, the molecular mechanisms CDK4/6 SCLC remain poorly understood. Here, Rb1
<title>Abstract</title> Our study elucidates the role of FOXP1 in chemoresistance SCLC. enhances by regulating SP8 expression through its super-enhancer (SP8-SE), with mediating resistance via homologous recombination repair (HRR) pathway. We also discovered that forms punctate nuclear structures indicative liquid-liquid phase separation <sup>1</sup>, crucial for transcriptional regulation. Targeting FOXP1-SP8-HR axis BRD4 and PARP inhibitors showed synergistic effects reducing tumor growth...